Delving into the Latest Updates on UCB Trading (Shanghai) Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Immune System Diseases

Monoclonal antibody

Small molecule drug

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	5
Immune System Diseases	3
Hemic and Lymphatic Diseases	1
Neoplasms	1
Infectious Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	4
Monoclonal antibody	2
Bispecific antibody	1

Top 5 Target	Count

FcRn(IgG receptor FcRn large subunit p51)	1
CD40L(CD40 ligand)	1
Sodium channels	1
SV2A(Synaptic vesicle glycoprotein 2A)	1
IL-13 x IL-17A x IL-17F	1

本研究的主要目标是在中国健康受试者中评估单次口服给药后 PSL及其 2 种代谢物（去甲基代谢物 [UCB1431322-000] 和羧酸代谢物 [UCB1447499 000])的 PK 特征。本研究的次要目标是在中国健康受试者中评估单次口服给药后 PSL 的安全性和耐受性。

[Translation]

The primary objective of this study was to evaluate the PK characteristics of PSL and its 2 metabolites (desmethyl metabolite [UCB1431322-000] and carboxylic acid metabolite [UCB1447499 000]) after a single oral dose in healthy Chinese subjects. The secondary objectives of this study were to evaluate the safety and tolerability of PSL after a single oral dose in healthy Chinese subjects.

Start Date14 Nov 2019

Sponsor / Collaborator

UCB Trading (Shanghai) Co., Ltd.

[+1]

CTR20160914

/ CompletedPhase 3

一项多中心开放长期扩展研究评价拉考沙胺作为联合疗法用于治疗儿童部分性发作癫痫受试者的有效性和安全性

[Translation] A multicenter, open-label, long-term extension study evaluating the efficacy and safety of lacosamide as combination therapy in the treatment of pediatric subjects with partial-onset epilepsy

主要目的：评估拉考沙胺在儿童受试者中的长期安全性和耐受性。次要目的：评估拉考沙胺在儿童受试者长期暴露期间的有效性。其他目的：评估儿童受试者在长期拉考沙胺暴露期间的行为、认知、生活质量和发育。

[Translation]

Primary objective: To evaluate the long-term safety and tolerability of lacosamide in pediatric subjects. Secondary objective: To evaluate the efficacy of lacosamide during long-term exposure in pediatric subjects. Other objectives: To evaluate the behavior, cognition, quality of life, and development of pediatric subjects during long-term lacosamide exposure.

Start Date19 Oct 2018

Sponsor / Collaborator

Aesica Pharmaceuticals GmbH

[+3]

100 Clinical Results associated with UCB Trading (Shanghai) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with UCB Trading (Shanghai) Co., Ltd.

Login to view more data

100 Deals associated with UCB Trading (Shanghai) Co., Ltd.

Login to view more data

100 Translational Medicine associated with UCB Trading (Shanghai) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

1

5

Phase 3

Approved

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Lacosamide ( Sodium channels )	Epilepsy More	Phase 3
Fenfluramine Hydrochloride ( 5-HT1D receptor x 5-HT2A receptor x 5-HT2C receptor x SERT x σ1 receptor )	Rett Syndrome More	Phase 3
Dapirolizumab pegol ( CD40L )	Systemic Lupus Erythematosus More	Phase 3
Alprazolam ( DOCK5 x GABAA receptor )	Epilepsy, Absence More	Phase 3
Galvokimig ( IL-13 x IL-17A x IL-17F )	Bronchitis, Chronic More	Phase 2